Abstract
Renal function was determined before and at varying times after chemotherapy in 62 patients with metastatic germ cell tumours treated with carboplatin. Eighteen patients were excluded because of urinary tract obstruction, leaving 44 evaluable patients treated with carboplatin either as a single agent (13 patients) or in combination with other agents (31 patients). No significant differences were observed in mean 51Cr-labelled Ethylenediamine tetraacetic acid (EDTA) clearances before and after carboplatin in either the group as a whole (P = 0.58), or when assessment at 1 month or less (P = 0.4), 3 months or less (P = 0.91), or later than 3 months (P = 0.38) were analysed. Carboplatin does not have significant renal toxicity when used at conventional dosage in patients with germ cell tumours.
Highlights
Eighteen patients had hydronephrosis or evidence of encroachment of disease onto the urinary tract, and they were excluded from the statistical analysis irrespective of their change in renal function after carboplatin, leaving 31 patients treated with CEB and 13 treated with carboplatin who were eligible for analysis
The mean carboplatin doses received by the 44 evaluable patients were 757.3 mg in those treated with single agent carboplatin, and 739.4 mg in those treated with CEB
It is estimated that the individual accuracy for serial estimations of Glomerular filtration rate (GFR) by this method will be within 10%, and it is apparent that most patients experienced no significant change or an improvement in renal function following treatment with carboplatin
Summary
Sixty-two patients with metastatic germ cell tumours were treated with either single agent carboplatin (21 patients, mean age 35.8 years, range 23-58 years) or carboplatin plus bleomycin and etoposide (CEB; 41 patients, mean age 28 years, range 10-48 years). Eighteen patients had hydronephrosis or evidence of encroachment of disease onto the urinary tract, and they were excluded from the statistical analysis irrespective of their change in renal function after carboplatin, leaving 31 patients treated with CEB and 13 treated with carboplatin who were eligible for analysis. Patients treated with single agent carboplatin received a dose of 400 mg m-2 repeated every 3 weeks to a maximum of six courses, with dose modifications for GFR of 120 ml min-' as described elsewhere (Horwich et al, 1989). The carboplatin dosage for patients treated with CEB was calculated on the basis of the EDTA clearance according to the formula. Received 19 July 1990; and in revised form 30 November 1990
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
